Analysts spread the love as Biogen Idec excites on MS, Alzheimer's

Analysts like to take an early front-row seat on a hot biotech company likely to please the market with a looming set of data. So, as Biogen Idec's ($BIIB) R&D chief Doug Williams already primed expectations earlier with his remarks on promising results seen in early-stage results for its Alzheimer's drug BIIB037, tomorrow's big reveal has focused a bright beam of attention on the company. Credit Suisse analyst Ravi Mehrotra is amped up about 037 as well as anti-LINGO, which is exploring a new approach to repairing the damage that causes multiple sclerosis. He sees each of these drugs as potential blockbusters able to amass more than $5 billion a year in peak sales. And that has quite a few analysts predicting that the company's shares, which have been steaming ahead, are set for another hike. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.